| 1 |
35088684 | Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma. | 2022 Jan 28 |
1 |
| 2 |
35158819 | Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. | 2022 Jan 22 |
1 |
| 3 |
35615894 | Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report. | 2022 May 26 |
1 |
| 4 |
32515291 | Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer. | 2021 Apr |
3 |
| 5 |
33662667 | Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer. | 2021 Apr 16 |
1 |
| 6 |
33744388 | Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. | 2021 Jun 1 |
3 |
| 7 |
34660806 | Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer. | 2021 |
1 |
| 8 |
34781244 | One-shot dual gene editing for drug-resistant pancreatic cancer therapy. | 2021 Dec |
3 |
| 9 |
31838939 | Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. | 2020 Mar |
1 |
| 10 |
32655498 | A Novel E2F1-EP300-VMP1 Pathway Mediates Gemcitabine-Induced Autophagy in Pancreatic Cancer Cells Carrying Oncogenic KRAS. | 2020 |
2 |
| 11 |
32828430 | Induction of potent cell growth inhibition by schizophyllan/K-ras antisense complex in combination with gemcitabine. | 2020 Sep 15 |
1 |
| 12 |
33216236 | Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment. | 2020 Nov 20 |
1 |
| 13 |
31508487 | ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. | 2019 Sep 27 |
1 |
| 14 |
29564165 | A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. | 2018 Feb |
1 |
| 15 |
29596326 | Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. | 2018 Mar 29 |
1 |
| 16 |
30083262 | Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. | 2018 |
1 |
| 17 |
30217561 | KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. | 2018 Dec 1 |
3 |
| 18 |
28060183 | Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells. | 2017 Feb |
2 |
| 19 |
28407465 | KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. | 2017 May |
1 |
| 20 |
28961832 | Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. | 2017 Oct 1 |
1 |
| 21 |
27101576 | miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation. | 2016 Oct |
1 |
| 22 |
27335026 | TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. | 2016 Aug |
1 |
| 23 |
25946136 | Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. | 2015 |
2 |
| 24 |
26156229 | The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. | 2015 Jul 10 |
2 |
| 25 |
24960403 | Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. | 2014 Jul 29 |
4 |
| 26 |
25216706 | Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity. | 2014 Oct |
1 |
| 27 |
23724098 | Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. | 2013 |
1 |
| 28 |
21289082 | Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. | 2011 Apr |
1 |
| 29 |
21738581 | Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. | 2011 |
1 |
| 30 |
21862683 | Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. | 2011 Oct |
2 |
| 31 |
21894049 | KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. | 2011 |
1 |
| 32 |
22966286 | Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. | 2010 Mar |
1 |
| 33 |
18430374 | Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells. | 2008 May |
1 |
| 34 |
17489984 | K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. | 2007 Jul |
1 |